45b4921e-fce7-41f8-bb63-ed98343ceec8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 48
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- MYOGENESIS+0.500
- COAGULATION+0.440
- APICAL_JUNCTION+0.410
- ANGIOGENESIS+0.360
- HEDGEHOG_SIGNALING+0.350
- TNFA_SIGNALING_VIA_NFKB+0.350
- IL2_STAT5_SIGNALING+0.320
- COMPLEMENT+0.310
- KRAS_SIGNALING_UP+0.310
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.410
- MITOTIC_SPINDLE-0.360
- PROTEIN_SECRETION-0.340
- MTORC1_SIGNALING-0.330
- PI3K_AKT_MTOR_SIGNALING-0.190
- DNA_REPAIR-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8392884 | — | cohortA1 | 0.933 |
| 2 | GSM5359443 | — | — | 0.933 |
| 3 | TCGA-AC-A3BB-01A-21R-A19W-07 | — | A | 0.926 |
| 4 | SRR12475155 | — | — | 0.926 |
| 5 | b65a6759-a9a4-4740-a9e3-962771dd9954 | — | — | 0.923 |
| 6 | 7c6f92ab-6cf8-4293-b676-2619c40f6ee6 | — | — | 0.922 |
| 7 | MDT-AP-0384 | Med | Medulloblastoma | 0.919 |
| 8 | TCGA-BH-A0BQ-01A-21R-A115-07 | — | A | 0.917 |
| 9 | TCGA-55-7281-01A-11R-2039-07 | — | cohortA1 | 0.917 |
| 10 | SRR27320696 | — | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| MYOGENESIS | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |